The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome : A Randomized Controlled Study by Holster, Savanne et al.
The Effect of Allogenic Versus Autologous Fecal
Microbiota Transfer on Symptoms, Visceral Perception
and Fecal and Mucosal Microbiota in Irritable Bowel
Syndrome: A Randomized Controlled Study
Savanne Holster, MSc1, Carl Mårten Lindqvist, PhD1, Dirk Repsilber, PhD1, Anne Salonen, PhD2, Willem M. de Vos, PhD2,3,
Julia Ko¨nig, PhD1 and Robert J. Brummer, MD, PhD1
OBJECTIVES: Fecal microbiota transfer (FMT) is suggested as a potential treatment for patients with irritable bowel
syndrome (IBS). We aimed to study the effect of allogenic and autologous FMT on IBS symptoms,
visceral sensitivity, and compositional changes in fecal and mucosa-adherent microbiota.
METHODS: Seventeen patients with IBS were randomized either to receive fecal material from a healthy donor
(allogenic) or to receive their own fecal material (autologous). The fecal material was administered into
the cecum by whole colonoscopy after bowel cleansing.
RESULTS: No significant differences were found between the allogenic and the autologous FMT regarding
symptom scores. However, symptom scores of patients receiving allogenic fecal material significantly
decreased after FMT compared with baseline (P5 0.02), which was not the case in the autologous
group (P50.16). Visceral sensitivity was not affected except for a small beneficial effect on urge scores
in the autologous group (P < 0.05). While both fecal andmucosa-adherent microbiota of some patients
shifted to their respective donor’s fecal microbiota, some patients showed no relevant microbial
changes after allogenic FMT. Large compositional shifts in fecal andmucosa-adherent microbiota also
occurred in the autologous group.
CONCLUSIONS: This study showed that a single FMT by colonoscopy may have beneficial effects in IBS; however, the
allogenic fecal material was not superior to the autologous fecal material. This suggests that bowel
cleansing prior to the colonoscopy and/or processing of the fecal material as part of the FMT routine
contribute to symptoms and gut microbiota composition changes in IBS.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A30
Clinical and Translational Gastroenterology 2019;10:e-00034. https://doi.org/10.14309/ctg.0000000000000034
INTRODUCTION
Fecal microbiota transfer (FMT) aims at introducing a new gut
microbiota to the gastrointestinal system of a patient. It is found
to be a safe, highly successful treatment in recurrent Clostridium
difficile infection with cure rates of 90% and higher (1,2). Also,
other diseases in which the gut microbiota plays a role became of
interest for treatment with FMT. Placebo-controlled clinical
studies in inflammatory bowel disease have shown that FMT
leads to remission in 24%–30% of patients with ulcerative colitis
(3–5). Similarly, studies in metabolic syndrome have shown that
healthy donor FMT can improve insulin sensitivity (6,7). Due to
the increasing evidence that a disturbed gut microbiota also plays
a role in the pathophysiology of irritable bowel syndrome (IBS),
FMT has been suggested as a potential treatment to improve
symptoms in this study population. A recent randomized
placebo-controlled clinical trial has studied the effect of FMT
administered by colonoscopy on symptoms in 90 patients with
IBS (8). More patients in the treatment group (65%) showed
a decrease in IBS-severity scoring system (IBS-SSS) score of more
than 75 points compared with the placebo group (43%) after 3
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months; however, this was not significant anymore after 12
months (56% vs 36%). In an additional recent randomized clin-
ical trial, the effect of FMT administered by capsules in 52 IBS
patients was investigated. Although intake of the capsules over 12
days resulted in changes to the gut microbiota of the IBS patients
in the treatment group, the symptom improvement after 3
months was larger in the placebo compared with the treatment
group (9).
Nowadays, typical characteristics of a healthy gut microbiota
are still not known. In IBS patients, butyrate-producing bacteria
in fecal samples seem to be reduced compared with healthy
subjects (10). Butyrate is a short-chain fatty acid produced in the
large intestine by microbial fermentation of undigested dietary
carbohydrates. It is the main energy source for colonocytes and
has shown to have anti-inflammatory, anticarcinogenic and
barrier-protecting properties (11). Butyrate enemas have shown
to decrease visceral sensitivity in healthy volunteers and might
decrease inflammation in inflammatory bowel disease (12,13).
Previous studies demonstrated that the amount of butyrate-
producing bacteria could be increased by FMT (7). Here, we
describe the outcome of a controlled study investigating FMT in
IBS, in which we included donors with a high abundance of
butyrate-producing bacteria in their fecal samples and IBS
patients with a low abundance of butyrate-producing bacteria.
Apart from studying the effect of FMT on the symptoms of IBS
patients, also its effect on the patients’ visceral sensitivity and on
the compositional changes in fecal and mucosa-adherent
microbiota were assessed in order to propose mechanistic
explanations for the observed responses.
METHODS
The study was conducted according to the principles of the
Declaration ofHelsinki and its revisions, and ethical approval was
obtained from the Central Ethical Review Board of Uppsala,
Sweden (registration number 2013/180). The study was per-
formed at O¨rebro University Hospital in O¨rebro, Sweden, from
May 2014 to April 2016. All participants were recruited in the
greater area of O¨rebro and gave their written informed consent
before participation. The trial has been registered at Clin-
icalTrials.gov (NCT02092402) on March 20, 2014.
Subjects
Patients. Adult IBS patients that fulfilled the Rome III diagnostic
criteria for IBS were included in this study (14). All IBS subtypes,
including postinfectious IBS, were eligible for the study. Reasons
for exclusion were any other known organic gastrointestinal
disease, previous complicated gastrointestinal surgery, non-
gastrointestinal malignancy, dementia, severe depression, major
psychiatric disorder, severe endometriosis, recent diagnosis of
lactose intolerance, celiac disease, pregnancy or breast-feeding,
antimicrobial treatment within 4 weeks prior to first screening
visit, regular consumption of probiotics within 4 weeks prior to
randomization, abuse of alcohol and drugs, or any other clinically
significant disease/condition which in the investigator’s opinion
could interfere with the results of the trial. The patients were
asked to keep their medication and diet stable over the entire
study period. Only IBS patients with a low amount of butyrate-
producing bacteria in their fecal samples were included. These
bacteria were quantified by quantitative real-time polymerase
chain reaction (qPCR) detection of the butyryl-CoA CoA trans-
ferase gene, encoding the last step of butyrate formation by gut
bacteria (15). IBS patients with less than 50% abundance of this
gene in the screening sample were compared to donor 1 qualified
for enrolment.
Donors.Healthy subjectswere carefully screened before inclusion
as donors. The exclusion criteria for donors are shown in Table 1
(16). Even though the use of proton pump inhibitors was not
a specific exclusion criterion, none of the donors were taking
proton pump inhibitors. All potential donors were screened for
butyrate-producing bacteria in their fecal samples as described
above for the IBS patients (15). The subject with the highest
abundance of the butyryl-CoACoA transferase gene in their fecal
sample was selected as donor. After this donor was no longer
available, a second donor was selected based on high abundance
of this gene. Both donors regularly visited the research facility to
donate fresh fecalmaterial and underwent regular blood and stool
tests during their participation in the study. The first 3 patients in
the treatment group received stool from donor 1, the remaining 5
from donor 2.
Sample size calculations
Sample size calculations showed that to detect 30% difference in
symptoms according to the gastrointestinal symptom rating scale
(GSRS)-IBS upon allogeneic FMT treatment, compared with 5%
difference after autologous treatment, with 80% power, the
sample size in each group should be n5 8. As this was a proof-of-
Table 1. Exclusion criteria for donors
Current communicable diseases
Known organic gastrointestinal disease
Gastrointestinal malignancy or polyposis
History of major gastrointestinal surgery
Eosinophilic disorders of the gastrointestinal tract
Known or high risk of infectious diseases such as HIV or hepatitis
Nongastrointestinal malignancy
Dementia, severe depression, major psychiatric disorder
Metabolic syndrome
Autoimmune diseases
Allergies
Chronic pain syndromes
Severe or morbid obesity
Pregnancy or breast-feeding
Use of immunosuppressive or chemotherapy agents
Antimicrobial treatment within last 6 months
Abuse of alcohol or drugs
Tattoo or body piercing obtained within the 6 months before screening
High-risk sexual behaviours
Travelling to areas with endemic diarrhea during 3 months before screening
Positive stool tests for Clostridium difficile toxin, enteral pathogensa, ova,
parasites, Giardia antigen, cryptosporidium antigen
Positive blood tests for HIV, Hepatitis A, B, or C
aSalmonella, Shigella/enteroinvasive E. coli (EIEC), Campylobacter,
enterohaemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), Yersinia
enterocolitica, Vibrio and Plesiomonas shigelloides.
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concept study using a per-protocol analysis, we aimed at in-
cluding 8 evaluable patients per group, thus 16 patients in total.
The subjects not completing the trial were replaced.
Study design, randomization, and masking
In this randomized controlled double-blinded study, the effect of
FMT on IBS patients was studied. The subjects were randomized
in a 1:1 manner to either the allogenic group, consisting of in-
fusion of fecal material from a healthy donor, or the autologous
group, in which subjects received their own fecal material, pro-
cessed in the same way as the allogeneic samples. The randomi-
zation list was generated by a researcher not involved in the study.
Shortly before a scheduled intervention visit, this researcher re-
moved any information about allogenic or autologous treatment
from the respective intervention, relabeled it with the day of in-
tervention and the recipient’s study code, and relocated the un-
used transplant in a freezer inaccessible to the researchers
involved in the study. All participants and investigators remained
blinded until the analyses of the primary outcome and the
symptom scale data were completed. Statistical analysis of all the
symptom scale data was performed blinded.
Fecal microbiota transfer procedure
The fecal material used for the FMT from the donors and patients
was collected directly at the research facility. A total of 30 g of
freshly delivered feces were carefully mixed with 0.9% sterile sa-
line solution and then passed through a sterilized stainless steel
strainer to remove larger particles. Then, 10% glycerol was added
to a final volume of 150 mL (17). The fecal suspension was stored
at280 °C until use, for a maximum of 3 months.
The donor or autologous fecal material was administered into
the cecum by colonoscopy. On the day before the colonoscopy,
patients underwent a routine bowel cleansing to remove as much
as possible of their own commensal gut microbiota and to facil-
itate the colonoscopy. Patients received 4 mg loperamide before
the colonoscopy to retain the transplant. The colonoscopy was
performed with support of mild sedation and carbon dioxide
inflation in order to avoid oxygen exposure.
Primary and secondary outcomes
The primary outcome was the effect of FMT on IBS symptoms
using the IBS version of theGSRS-IBS. TheGSRS-IBS is a reliable,
validated IBS-specific symptom scale (18). It includes 13 items in
5 symptom clusters (abdominal pain, bloating, constipation, di-
arrhea, and satiety) and measures symptoms during the past 7
days with a 7-point Likert scale ranging from 1 (no discomfort at
all) to 7 (very severe discomfort). The participants completed the
GSRS-IBS 2 weeks and 1 day before the FMT, as well as 2 weeks,
4 weeks, 8 weeks, and 6 months after the FMT, respectively.
Secondary outcomes were the effect of FMT on the patients’
IBS symptoms using the IBS-SSS (19,20), their general health and
quality of life (36-item Short Form Survey (SF-36) (20) and IBS-
QoL (21)), as well as their anxiety and depression status using the
hospital anxiety and depression scale (22). The IBS-SSS was
assessed at the same time points as the GSRS-IBS, while the other
scales were completed before as well as 2 and 8 weeks after the
FMT. In addition, secondary outcomes included the effect of
FMT on the IBS patients’ visceral perception (pain, discomfort,
and urge scores on a visual analogue scale (VAS) during barostat
procedure), as well as the effect on IBS patients’ fecal andmucosal
microbiota composition (HITChip analysis) (23).
Symptom improvement of 30% was considered clinically
relevant, and thus, responders to FMT treatment were defined by
a decrease of 30% in the total GSRS-IBS symptom score at one of
the assessed time points after FMT.
Adverse event assessment
Adverse events during the first week following the FMT were
recorded daily by the participants using a written form that in-
cluded documentation of body temperature. Subsequently, ad-
verse events were recorded directly by the investigators at every
study visit.
Visceral sensitivity assessment using the barostat procedure
Subjects fasted for 12 hours before assessment and were placed in
a left lateral position to reduce the influence of adipose tissuemass
and abdominal wall tone. The barostat catheter (600 mL; Mui
Scientific, Ontario, Canada) was placed 10–15 cm into the rec-
tum. Rectal distensions were performed according to our pre-
vious studies using an electronic distension device (Electronic
barostat, distender series II; G & J Electronic, Toronto, Ontario,
Canada) (24). First, theminimal distension pressure was assessed
and set to zero as a reference point during the measurement of
visceral sensitivity. For the latter, intermittent semi-random
staircase distensions of 60 seconds duration (15, 10, 25, and
20 mm Hg, etc.) were separated by intervals of 30 seconds of
baseline pressure. During each distension (after 30 seconds),
subjects were asked to report their perception of pain, discomfort,
and urge, respectively, using 100 mm VAS. The protocol was
stopped when the perceptual threshold for maximal tolerable
pain, discomfort, and/or urge was reached, or when the safety
value of the maximal pressure of 61 mm Hg was exceeded.
Microbiota profiling
Fecal samples were collected from the patients 2 weeks before
FMT, and 2 and 8 weeks after FMT. Samples were collected at
home, immediately placed into the home freezer and returned
frozen to the research facility where they were stored at280 °C.
Donor fecal samples were directly collected by the investigators
from the samples donated for FMT. Mucosal biopsies from the
uncleansed sigmoid were collected by sigmoidoscopy at a stan-
dardized location (20–25 cm from the anal verge at the crossing
with the arteria iliaca communis) from the patients 2weeks before
FMT, and 2 and 8 weeks after FMT, and from the donors at one
occasion. Microbial DNA from fecal samples was isolated using
repeated bead beating (25) and the QIAamp DNA stool extrac-
tion kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. DNA concentration was assessed using
a Qubit spectrometer (Thermo Fisher Scientific, Boston, MA).
Microbial DNA from mucosal samples was isolated using re-
peated bead beating (25) with some adjustments, including
a proteinase K incubation prior to the mechanic cell disruption
and use of a Maxwell extraction robot (Maxwell 16 Tissue LEV
Total RNA Purification Kit; Promega, Madison, WI).
The abundance of the butyryl-CoA CoA transferase gene in
fecal sample was assessed by qPCR performed with Applied
Biosystems 7900HT Fast Real-Time PCR system (Life Technol-
ogies, Carlsbad, CA) using 5x HOT FIREPol EvaGreen qPCR
Supermix (Solis BioDyne, Tartu, Estonia) and the primers
BCoATscrF (GCIGAICATTTCACI TGGAAYWSI TGGCAY
ATG) and BCoATscrR (CCT GCC TTT GCA ATR TCI ACR
AAN GC) (TAG Copenhagen A/S, Copenhagen, Denmark).
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DNA was diluted to 5 ng/mL before PCR amplification. The
thermal cycling conditions of the qPCR was set to 95 °C for 15
minutes, followed by 40 cycles of 95 °C for 15 seconds, 53 °C for 20
seconds, 72 °C for 30 seconds, and ended with one cycle of 95 °C
for 1 minute and 50 °C for 30 minutes.
Fecal and mucosal microbial composition were separately
assessed using the Human Intestinal Tract Chip (HITChip),
a customized Agilent microarray, as previously described (23)
with minor modifications as described (6). The HITChip is
a phylogeneticmicroarray based on 16S rRNA sequences of 1,033
phylotypes present in the human intestinal tract and allows deep
analysis of the bacterial community, as observed by comparisons
with 16S rRNA amplicon sequencing and metagenomics
(23,26,27). The hybridization signals are normalized and sum-
marized to 130 genus-like phylogenetic groups (level 2, .90%
16S rRNA gene sequence similarity), referred to as species and
relatives (23). Since all HITChip data are generated using 2 in-
dependent analyses with Cy3 and Cy5 labels (23), it provides
a highly reproducible, comparable, and accuratemethod to assess
the bacterial composition and has been used successfully in other
FMT studies (5,7,28).
Data analysis
Questionnaire data. All values were baseline-corrected to ac-
count for interindividual differences. For the IBS-SSS and GSRS-
IBS scales, the average of the 22 weeks and 21 day values was
used as the baseline value. Statistical differences between the
allogenic and autologous group were assessed with the Mann-
Whitney U-test. Friedman’s test was performed on baseline-
corrected data to detect significant differences between the time
points within the groups. Post hoc testing was performed with
the Wilcoxon signed rank test. Descriptive P-values (not ad-
justed for multiplicity) are reported for all tests comparing
questionnaire results.
Barostat data. The parameters of the logistic functions with in-
tercept of the measured VAS-scores for pain, discomfort, and
urge, respectively, at the fixed pressures of 20, 30, 40, 50, and
60 mm Hg, were estimated. The fitted baseline-corrected VAS
values were then compared before and after FMTusingWilcoxon
signed rank test, and between allogenic and autologous using
Mann-Whitney U-test. Descriptive P-values were reported. For
details, see Supplemental Methods (see Supplementary Digital
Content 1, http://links.lww.com/CTG/A30).
Microbiota data. HITChip data were normalized to relative
abundance by dividing all intensities by the sum of all intensities
for each sample. All analyses were performed on genus-like
phylogenetic level with the aim to assess whether the FMT had
community-level effects on the microbiota. Shannon diversity
index was calculated using function “diversity” from the
R-package vegan (29,30). Baseline corrections were performed by
subtracting the diversity at baseline from values at week 2 and 8,
respectively, for each patient. Similarity indices were calculated as
pairwise Pearson correlations (function rcorr, from R-package
Hmisc). Baseline-corrected diversity and similarity indices were
compared before and after FMT usingWilcoxon signed rank test.
Descriptive P-values were reported. Redundancy analysis (RDA)
was performed (function rda, R-package vegan) as followed:
Explanatory variables were (i) time points, coded as dummy
variables, and (ii) status of a sample as donor sample or recipient
sample. These explanatory variables served to explain microbiota
composition in all samples. RDA was applied to both scaled and
unscaled microbiota data, where scaling was implemented as
standardization, that is, mean value subtraction and division by
standard deviation. Principal component analysis was performed
on the relative abundance composition data (scaled data) using
prcomp-function in R version 3.3.0 with scaled set to true. R
version 3.3.0 was used for the analysis (31).
RESULTS
Participants
Out of 34 potential participants, 17 IBS patients with a fecal micro-
biota low in butyrate production capacity were included and ran-
domly assigned to either the allogenic group, receiving fecal material
from a healthy donor, or the autologous group, receiving their own
fecal material (see Figure 1, Supplementary Digital Content 1, http://
links.lww.com/CTG/A30). One participant discontinued the study
after the FMT due to discomfort during the procedures (autologous
group). This participantwas replacedwith a new subjectwhodid not
continue with the sigmoidoscopies and barostat procedure after the
FMT due to discomfort during these procedures, but completed the
symptom scales and provided fecal samples. Another participant
(autologous group) chose not to undergo the second barostat ex-
aminationdue todiscomfort during thepreviousprocedure.Baseline
Table 2. Baseline characteristics
Allogenic
(n5 8)
Autologous
(n 5 8) P value
Age, median (IQR) 34 (27–49) 39 (33–43) 0.29
Sex, m/f 5/3 3/5 0.62
BMI (kg/m2),
median (IQR)
20.9
(20.2–25.1)
22.7
(20.7–24.3)
0.87
Classification,
IBS-D/IBS-C/IBS-M
5/1/2 4/3/1 1.0/0.57/1.0
Postinfectious IBS 4 4 1.0
Disease duration,
unknown/1–5 yr/5 yr
0/4/4 1/3/4 1.0/1.0/1.0
Concomitant
medication
7 6 1.0
Gut-related medication 3 3 1.0
Laxatives 1 2a 1.0
Antidiarrheal 1 1 1.0
Antispasmodic 1 1 1.0
Antidepressants 5 3 0.62
SSRIs 5 0 0.03
NaSSAs 0 2 0.47
SSNRIs 0 1b 1.0
TCAs 0 1b 1.0
BMI, body mass index; C, constipation; D, diarrhea; IBS, irritable bowel
syndrome; IQR, interquartile range; M, mixed classification; NaSSA,
noradrenergic and specific serotonergic antidepressant; SSNRI, selective
serotonin noradrenalin reuptake inhibitor; SSRI, serotonin reuptake inhibitor;
TCA, tricyclic antidepressant.
aOne participant took 2 different types of laxatives.
bOne participant took both SSNRI and TCA.
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characteristics of the included participants are presented in Table 2
and did not significantly differ between the allogenic and autologous
groups.None of the participantswere taking protonpump inhibitors
during the study. While the overall use of antidepressant drugs was
similar in both groups, this use only comprised serotonin reuptake
inhibitors in the allogenic FMT group, while the IBS patients in the
autologous FMT group used other types of antidepressants. How-
ever, this should not affect the results.
Adverse events
No serious adverse events were reported. Four participants
reported adverse events in the allogenic group, and 7 in the au-
tologous group (Table 3).
Outcomes
Primary outcome.No significant differences in GSRS-IBS scores
between the allogenic and autologous groups were found. How-
ever, the GSRS-IBS scores of patients receiving donor fecal ma-
terial decreased significantly after FMT compared to baseline
(P , 0.05, Friedman’s test). This decrease was not significant in
the autologous group (P 5 0.16). Baseline-corrected GSRS-IBS
scores showed significantly decreased symptoms for the treat-
ment group at 2 weeks after FMT (allogenic: median 20.37,
interquartile range (IQR)20.68 to20.20, P, 0.05; autologous:
20.69, IQR -1.02 to20.04) and at 4 weeks after FMT (allogenic:
20.69, IQR21.39 to20.12, P, 0.05; autologous:20.60, IQR2
0.80 to 0.04), while this decrease was not significant after 8 weeks
and 6 months (Figure 1a). The decreased total symptoms scores
seemed to be driven by different symptom subscores in the 2
groups (Figure 1b–f). Numbers in this study are too small to
perform subgroup analyses, but symptom improvement did not
seem to be related to any specific subgroup.
Responders were defined by a decrease of at least 30% in the
total GSRS-IBS symptom score after FMT. In the allogenic group,
4 out of 8 patients showed a 30% decrease in GSRS-IBS total score
at one of the time points after FMT, while only 1 out of 8 patients
reached this symptom reduction in the autologous group. This
difference was not significant (P5 0.282, Fisher’s exact test). Two
out of 3 patients that receivedmaterial from donor 1 (66%), and 2
out 5 from donor 2 (40%) classified as responders (P 5 1.0,
Fisher’s exact test).
Secondary outcomes.
Questionnaire data.The IBS-SSS scores of patients receiving donor
fecal material decreased after FMT compared to baseline (P 5
0.05, Friedman’s test). This decrease in symptom score was
significant 4 weeks after FMT (median 270.6; IQR290.1 to2
10.5; P, 0.05), 8 weeks after FMT (269.3; IQR277.2 to219.3;
P, 0.05), and 6 months after FMT (236.4; IQR269.8 to23.5;
P, 0.05) (Figure 2). No significant differences in the autologous
group compared with baseline were observed (P 5 0.22) and
neither between allogenic and autologous treatment.
The IBS-QoL total score was significantly increased after FMT
compared to baseline in the allogenic group (P , 0.005, Fried-
man’s test), but not in the autologous group (P 5 0.50). This
increase in the allogenic group was significant 2 weeks and 8
weeks after FMT (2.9; IQR0.2–7.9;P, 0.05 and 9.6; 4.3, 15.6;P,
0.05, respectively) (Figure 3a). No statistical significance was
found between the allogenic and autologous groups.
Similar results were observed in 3 out of 8 SF-36 subscores,
especially in the “general health” subscore (Figure 3b). This score
was significantly increased in the allogenic compared with the
autologous group 8 weeks after FMT (10.0; IQR 10.0–19.8 com-
pared to 212.5; IQR 215.0 to 21.3; P , 0.01). No significant
differences in hospital anxiety and depression scale scores were
found between allogenic and autologous and between before and
after FMT (data not shown).
Visceral sensitivity. Complete barostat data were available from
n5 14 participants. TheVAS scores at 20, 30, 40, and 50mmHg
were estimated from the fitted logistic curves, before and 8weeks
after FMT. No significant differences were found before and
after FMT in the allogenic (n 5 8) and the autologous group
(n5 6) for perception of pain and discomfort, respectively. The
perception of urge was significantly lower in the autologous
group compared with the allogenic group 8 weeks after the FMT
at 20mmHg (21.9; IQR22.3 to20.7 vs20.4; IQR20.6 to 0.2,
P, 0.05), 40 mmHg (21.6; IQR22.6 to20.7 vs 0.3; IQR20.6
to 1.9, P, 0.05) and 50mmHg (20.8; IQR21.3 to20.3 vs 0.3;
IQR20.4 to 2.1, P, 0.05) (Figure 4). The patients with a pos-
itive symptom response did not show a decrease in visceral
sensitivity, and no differences according to subtypes were noted.
Microbiota profiling. Bacterial DNA extracted from fecal samples
(n 5 54, from 16 patients and 2 donors) and mucosal biopsies
(n 5 47, from 15 patients and 2 donors) was analyzed by
HITChip. Two mucosal samples in the autologous group could
not be analyzed due to insufficient amplifiableDNA (n5 1 from2
weeks after FMT, n5 1 from 8 weeks after FMT).
Redundancy analysis. Figure 5 shows RDA biplots of the bacterial
composition of fecal and mucosal samples, respectively, with fac-
torization of time points and donor status as response variables,
Table 3. Adverse events in the allogenic and autologous group
Allogenic
(n5 8)
Autologous
(n5 8) P value
Any adverse event 4 7 0.28
Gastrointestinal pain or cramps 3 3 1.0
Bloating/flatulence 3 3 1.0
Diarrhea 2 2 1.0
Constipation 0 1 1.0
Nausea 2 0 0.46
Anal pain during defecation 1 0 1.0
Hemorrhoids 0 1 1.0
Headache 0 3 0.2
Hot flashes 1 0 1.0
Discoloured fecal lumps 0 1 1.0
Fever 0 0 1.0
Elevated temperature
(37.5 °C–38.5 °C)
0 2 0.47
Tiredness 0 1 1.0
General muscle ache 0 1 1.0
Thirst 0 1 1.0
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including the most important bacterial genera. Examining the
resulting ordinations, fecal samples from the allogenic group2and8
weeks after FMT seemed to cluster closer to their corresponding
donor than the baseline samples or the samples from the autologous
group, especially for recipients of fecal material from donor 1
(Figure 5a). This pattern was also observed, however to a lesser
degree, comparingmucosalmicrobiota frompatients to the donors’
fecal microbiota (Figure 5b), or when scaling the raw values to zero
mean and unit variance (Figures 5d, e), allowing the representation
of bacterial genera with a lower abundance to affect the results in
a similar degree as genera with high abundance values.
The mucosal microbiota of the recipients did not seem to cluster
closely to the mucosal microbiota of the donors (Figure 5c, f).
The bacterial genera for which the variations explained most of the
microbiota’s total variation are also depicted in Figure 5. Principal
component analysis plots of the bacterial composition are depicted in
Supplemental Figure 2 (see Supplementary Digital Content 1, http://
links.lww.com/CTG/A30). While some of the subjects in the allo-
genic group shifted toward their corresponding donor, the micro-
biota in the autologous group also changed over time (see Figure 2,
Supplementary Digital Content 1, http://links.lww.com/CTG/A30).
Shannon diversity and Pearson’s similarity index. The Shannon di-
versity was calculated for both the fecal and themucosalmicrobiota
samples. The microbial diversity in our study population was not
significantly affected by allogenic or autologous FMT, neither in the
fecal nor in the mucosal samples (see Figure 3, Supplementary
Digital Content 1, http://links.lww.com/CTG/A30). The patients
Figure 1. Baseline-corrected GSRS-IBS scores at different time points after FMT. Median and interquartile ranges (IQRs) are shown. (a) Total scores.
(b–f) Respective subscores. No statistical significancewas foundbetween the allogenic and the autologous groups. In the allogenic group, total scoreswere
significantly reduced 2 weeks and 4 weeks after FMTcompared with baseline. *P, 0.05. GSRS-IBS, gastrointestinal symptom rating scale, IBS version.
Clinical and Translational Gastroenterology VOLUME 10 | APRIL 2019 www.clintranslgastro.com
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with a positive symptom response did not show increased fecal or
mucosal microbiota diversity.
Supplemental Figure 4A (see Supplementary Digital Content,
http://links.lww.com/CTG/A30) shows the Pearson correlation
for the allogenic group, in which the recipients’ fecal microbiota
composition was correlated to their corresponding donors’ fecal
microbiota. Even though the patients’ fecal microbiota seemed to
becomemore similar to the donors’microbiota over time, this did
not result in significant correlations (see Figure 4A and Table 1,
see Supplementary Digital Content, http://links.lww.com/CTG/
A30). The responders in the allogenic group generally showed an
increased similarity index (see Figure 4A, Supplementary Digital
Content, http://links.lww.com/CTG/A30).
Supplemental Figure 4B (see Supplementary Digital Content,
http://links.lww.com/CTG/A30) shows Pearson’s similarity index
for the autologous group, in which the patients’ fecal microbiota
was correlated to their own fecal microbiota at baseline. The
similarity index was significantly reduced 2 and 8 weeks after
the autologous FMT compared to baseline both in the fecal and
mucosal samples (see Table 2, Supplementary Digital Content,
http://links.lww.com/CTG/A30).
There was no significant correlation between the recipient’s
mucosal microbiota and the donor mucosal microbiota or fecal
microbiota in the allogenic group (see Figure 4C, E, Supple-
mentaryDigital Content, http://links.lww.com/CTG/A30). In the
autologous group, the recipient’s own mucosal microbiota after
the autologous FMT differed significantly from their mucosal but
not significantly from their fecal microbiota at baseline (see
Figure 4D, F and Supplemental Table 1, Supplementary Digital
Content, http://links.lww.com/CTG/A30).
Butyrate-producing bacteria. Even though low qPCR counts of
butyryl-CoA CoA transferase gene in the screening samples were
used as an inclusion criteria for the allogenic group, the
abundance of butyrate-producing bacteria in the fecal samples at
baseline, as assessed by theHITChip analysis, was not lower in the
allogenic group than in the donor group (see Figure 5A,
Supplementary Digital Content, http://links.lww.com/CTG/
A30). Additionally, no significant change in butyrate-producing
bacteria was found after FMT using fecal material from donors
with high qPCR counts of the butyryl-CoA CoA transferase gene
(see Figure 5B, Supplementary Digital Content, http://links.lww.
com/CTG/A30). In the autologous group, the amount of
butyrate-producing bacteria in the baseline samples of the
patients was lower than in the fecal samples of the donors (P 5
0.09; see Supplemental Figure 5A, C, Supplementary Digital
Content, http://links.lww.com/CTG/A30). Autologous FMT did
not significantly affect the amount of butyrate-producing bacteria
(see Figure 5C, Supplementary Digital Content, http://links.lww.
com/CTG/A30). Species defined as butyrate producers are listed
in Supplemental Table 3 (see Supplementary Digital Content,
http://links.lww.com/CTG/A30). Likewise, when analyzing these
samples for the counts of butyryl-CoACoA transferase gene with
Figure 2. Baseline-corrected IBS-SSS scores at different time points after
fecal microbiota transfer (FMT). Median and interquartile ranges (IQRs)
are shown. No statistical significant differences were found between the
allogenic and the autologous groups. In the allogenic group, total scores
were significantly reduced 4 weeks, 8 weeks, and 6 months after FMT
compared to baseline. *P, 0.05. IBS-SSS, IBS-severity scoring system.
Figure 3.Baseline-corrected quality of life (IBS-QoL) and health status (SF-36) scores at different time points after fecal microbiota transfer (FMT). Median
and interquartile ranges (IQRs) are shown. (a) IBS-QoL scores. No statistical significant differences were found between the allogenic and the autologous
groups. In the allogenic group, total scores were significantly increased 2 weeks and 8 weeks after FMTcompared with baseline. *P, 0.05. (b) Short form
36 (SF-36) subscore general health. Scores differed significantly between the allogenic and the autologous groups 8 weeks after FMT. **P, 0.01.
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qPCR, no significant effect of the FMTon the butyrate-producing
capacity was found (data not shown).
DISCUSSION
In this double-blinded, randomized controlled study, 17 patients
were treated with a single FMT via colonoscopy. No statistical
significances were found in the symptoms scores between the
allogenic group, which received fecal material from healthy
donors, and the autologous group, which received their own
autologous fecal material. However, the allogenic group had
significantly decreased symptom scores and increased quality-of-
life scores compared with baseline, which was not the case in the
autologous group. These results are in line with a recently
reported placebo-controlled study on the clinical efficacy of FMT
in IBS patients (8). In this study, a significantly higher number of
responders in the treatment group (FMT administered by colo-
noscopy) compared with the placebo group (autologous FMT)
was found (P 5 0.049). Even though 90 IBS patients were in-
cluded, the differences in symptoms scores between the treatment
and the placebo groups also did not reach significance (8). An
additional recent study using capsules for administering the FMT
in IBS patients also found symptom improvement in both
treatment and placebo groups. However, the placebo was sig-
nificantly favorable to the treatment in this study (9). The dif-
ference in results could be due to the different routes of delivery,
as administration by these capsules probably led to the release of
the transplant into the upper gastrointestinal tract. We chose
delivery by the lower gastrointestinal tract as we primarily wanted
to achieve colonization of a new microbiota in the colon.
In all studies, the placebo effect was higher than expected. It
could be that the bowel cleansing by itself already has a beneficial
effect on IBS symptoms. In healthy subjects, bowel cleansing has
been shown to have only a momentarily effect on the fecal
microbiota that usually recoverswithin 2weeks (32). It is unknown
how bowel cleansing specifically affects the gut microbiota of IBS
patients. In addition, it could be that the handling of the fecal
material during preparation for the autologous transplant sub-
stantially altered themicrobiota composition. The rationale behind
using autologous material is to study whether the effect of fecal
material from a healthy donor is more effective than the patients’
own stool. In our study, the use of bowel cleansing and autologous
stool resulted in considerable changes to the fecal and mucosal
microbiota 2 and even 8 weeks after the FMT, suggesting that this
might not be a true placebo in a pharmacological sense. Future
FMT studies in IBS could include a second control arm in which
patients only undergo bowel cleansing.
Themicrobial diversity in fecal samples of IBS patients included
in our study was not found to be significantly affected by either the
allogenic or autologous FMT. In the FMT in IBS study using cap-
sules, Halkjaer et al. (9) found that the fecal microbiota of IBS
patients at baseline was significantly lower in diversity compared
with the donors, whichwas no longer the case after FMT treatment.
The diversity in the placebo group was still significantly lower
compared with the donors after treatment, indicating that only the
intake of FMT capsules resulted in higher diversity. However, di-
versity did not correlate with symptoms. In our study, themicrobial
diversity of the IBSpatients at baselinewasnot lower than that of the
donors.Only few studies have investigated themicrobial diversity in
IBS in general, and results are conflicting, reporting both increased
and decreased diversity compared with healthy controls (33,34). In
Figure 4. Baseline-corrected VAS scores for visceral perception of pain
(a), discomfort (b), and urge (c) 8 weeks after fecal microbiota transfer
(FMT) at different pressures. No significant differences were found for
perception of pain and discomfort. The perception of urge was significantly
lower in the autologous group compared with the allogenic group. VAS,
visual analogue scale. *P, 0.05, **P, 0.01.
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Figure 5.Redundancy analysis (RDA) plots of the fecal andmucosal microbiota composition. Explanatory variables were (i) time points, coded as dummy
variables, and (ii) status of a sample as donor sample or recipient sample. These explanatory variables served to explain microbiota composition in all
samples. Unscaled (a–c) or scaled (d–f) values are shown. Scaled values allow the representation of bacterial genera with a lower abundance to the same
degree as genera with high abundance. (a and d) Fecal microbiota of patients and fecal microbiota of donors. (b and e) Mucosal microbiota of patients and
fecal microbiota of donors. (c and f) Mucosal microbiota of patients and mucosal microbiota of donors.
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general, varying microbial diversity could be explained by different
dietary habits (35).
In IBS, it is still unknown which patients are more likely to
respond to FMT. In our study, the sample size was too low to
perform proper subanalyzes based on IBS subtypes. However,
also Halkjaer et al. (9) could not detect subtype-specific effects of
FMT on symptoms. In addition, it is important to note that
patients classified by the same IBS subtype do not necessarily
display the same pathophysiology.
IBS patients in our study were included based on a relatively low
amount of butyrate-producing bacteria in their fecal samples using
amplification of the butyryl-CoA CoA transferase gene by real-time
qPCR (screening samples, often taken several weeks before the in-
tervention baseline samples). Accordingly, donors with a high
amount of this enzyme were selected. After randomization into al-
logenic and autologous groups, microbiota from the fecal samples
was analyzed usingHITChip.Unexpectedly, the amount of butyrate-
producers at baseline in the allogenic group was not lower compared
with thatof thedonors,which is a limitation regarding theoutcomeof
this study.This difference in butyrate producing-bacteria between the
screening and baseline samples could be due to technical reasons, for
example, differences between HITChip vs butyryl-CoA CoA trans-
ferase gene qPCR (36), slightly different protocols used for DNA
extraction of screening and baseline samples, and different storage
times. Additionally, natural temporal variations of butyrate-
producing bacteria in the fecal material of IBS patients could ex-
plain the differences observed between the screening and baseline
samples. It is not known how the abundance of these and other
bacteria vary over time in IBS patients and other study populations.
However, it has been suggested that butyrate-producing bacteria are
rather sensitive to everyday life variations (37).
Visceral hypersensitivity is common among IBS patients, with
a prevalence of 50%–90% (38). A possible role of the gutmicrobiota
in visceral hypersensitivity was suggested by a study that showed
that rats had increased rectal sensitivity compared with the control
group after colonization with gut microbiota of IBS patients (39).
Thus, altering the gut microbiota, for example, by FMT, could hy-
pothetically reduce hypersensitivity in IBS patients. In our study,
however, the decrease in symptoms scores did not seem to be me-
diated by reduced visceral hypersensitivity. Only in the autologous
group, a beneficial effect on the perception of urge could be ob-
served, possibly due to the bowel cleansing. That this was not the
case in the allogenic group could be due to a reaction of the host
mucosa to the introduction of a new, “foreign”microbiota.
A unique approach in this study was that we also collected
mucosal biopsies from the sigmoid, from both the patients and the
donors, and analyzed themicrobiota composition in those samples.
We could show that the mucosal microbiota of the recipients was
also affected by the newly introduced fecal microbiota, indicating
that FMT has the potential to affect the IBS patients’ host response.
Further research needs to identify the specific effects of FMT for
example on the mucosal immune response.
A limitation of this study is the low sample size number. Power
calculations were based on detecting 30% difference in symptoms
according to the GSRS-IBS upon allogenic FMT treatment,
comparedwith 5%difference after autologous treatment; thus, we
clearly underestimated the placebo effect. Nevertheless, we
showed similar effects on symptoms as Johnsen et al. (8) who
included n5 90 in their study. Patients participating in our study
underwent a rather extensive study protocol, including repeated
visits for assessment of visceral hypersensitivity (barostat) and
collection of biopsies by sigmoidoscopy at several time points
before and after the FMT. In addition, it is important to note that
our results were not corrected for multiple testing. An additional
limitation of this study is that even though participants were
asked to keep their diet stable, this was not confirmed by a vali-
dated method. Nevertheless, the research reported here gives
valuable insight into the physiological changes induced by FMT,
a potential treatment for IBS patients.
In conclusion, we showed that a single FMT via colonoscopy
could improve symptoms and quality of life in IBS patients,
however, not significantly superior to autologous FMT. FMT
seemed to affect both the fecal and the mucosa-adherent micro-
biota, but did not change visceral sensitivity. Future studies are
necessary to investigate whether the efficacy of FMT in IBS
patients can be improved by repeated FMTs, as often applied in
ulcerative colitis (3–5). In addition, future studies should aim at
further elucidating the mechanistic properties of FMT to be able
to offer effective, individualized treatments for IBS patients.
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Study Highlights
WHAT IS KNOWN
3 Gutmicrobiotamight play a role in the pathophysiology of IBS.
3 FMT has been suggested as a potential treatment to improve
symptoms in IBS.
WHAT IS NEW HERE
3 A single FMT by colonoscopy may have beneficial effects in
IBS.
3 Allogenic FMT (stool from healthy donors) does not seem to
be significantly superior to autologous FMT (own stool).
3 FMT has an effect on both fecal as well as mucosal
microbiota.
3 Already bowel cleansing and processing of the fecal material
(autologous FMT) have an effect on symptoms and fecal as
well as mucosal microbial composition.
TRANSLATIONAL IMPACT
3 Results of this study may give an insight in the physiological
changes induced by FMT in IBS patients.
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